Gold prices are pushing higher as the U.S. labor market showed further weakness as fewer American's found jobs in September, potentially putting a crimp in the Federal Reserve's plan to shift its monetary policy before the end of the year.
Numinus Upgrades Psychedelics Lab to Increase Research Service Capabilities
Numinus announces expansion of its psychedelics research facility and an application to Health Canada for a second Dealer's License.
Oklahoma Advocates Campaign to Put Cannabis Reforms on 2022 Ballots
Cannabis advocates in Oklahoma have filed ballot initiatives for 2022 to legalize adult-use cannabis and replace the current medical cannabis oversight agency, the Tulsa World reports.
Gold prices in Pakistan surge in line with global markets
The price of gold resumed its uptrend in the domestic market and rose by Rs800 to close at Rs115,000 per tola on Tuesday in line with the surge in the international bullion market.
Gold price near steady as fresh fundamental inputs awaited
Gold prices are trading near unchanged in early U.S. trading Wednesday.
Novamind Launches New Psychedelic Palliative Care Program
Novamind is expanding its mental health care to include the treatment of patients with palliative needs, via its new Murray, Utah treatment clinic.
The Ketamine Renaissance
Psychedelic drugs like psilocybin, LSD and MDMA have amazing medicinal and commercial potential. So does ketamine, but ketamine is already legal.
Here's Why Silver Could be Setting Up for a Strong Q4
Silver was down 16% in Q3 as the Fed begins to taper asset purchases.
Gold price headed to $5,500 in the long term as central banks won't be able to exit unorthodox monetary policies - Jefferies
The Federal Reserve's potential plan to reduce its monthly bond purchase by the end of the year continues to weigh on the gold market as prices remain tethered to support around $1,750 an ounce. However, one investment firm continues to see gold prices pushing thousands of dollars higher in the long-term.
PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease
PharmaTher initiates a Phase 2a clinical trial for a ketamine-based therapy for Parkinson's Disease, expected to commence in October 2021.
Levitee Labs Publishes First Revenue Figures for August 2021
Levitee Labs reports (unaudited) revenues of CAD$893,863 for the month of August from clinic operations.
Optimi Health Natural Psilocybin Extraction Breakthrough Submitted for Provisional Patent Application
Optimi Health files a provisional patent application for a stable extraction method for natural psilocybin.
